Attenuated psychosis syndrome in DSM-5
- PMID: 23773295
- PMCID: PMC3778120
- DOI: 10.1016/j.schres.2013.05.004
Attenuated psychosis syndrome in DSM-5
Abstract
Despite advances in the treatment of schizophrenia over the past half-century, the illness is frequently associated with a poor outcome. This is principally related to the late identification and intervention in the course of the illness by which time patients have experienced a substantial amount of socio-occupational decline that can be difficult to reverse. The emphasis has therefore shifted to defining psychosis-risk syndromes and evaluating treatments that can prevent transition to psychosis in these ultra-high risk groups. To consider the appropriateness of adding psychosis risk syndrome to our diagnostic nomenclature, the psychotic disorders work group extensively reviewed all available data, consulted a range of experts, and carefully considered the variety of expert and public comments on the topic. It was clear that reliable methods were available to define a syndrome characterized by sub-threshold psychotic symptoms (in severity or duration) and which was associated with a very significant increase in the risk of development of a full-fledged psychotic disorder (schizophrenia spectrum, psychotic mood disorder, and other psychotic disorders) within the next year. At the same time, the majority of individuals with "attenuated psychotic symptoms" had one or more other current psychiatric comorbid conditions (usually mood or anxiety disorders, substance use disorder; Fusar-Poli 2012) and exhibited a range of psychiatric outcomes other than conversion to psychosis (significant proportions either fully recover or develop some other psychiatric disorder, with a minority developing a psychotic disorder). Although the reliability of the diagnosis is well established in academic and research settings, it was found to be less so in community and other clinical settings. Furthermore, the nosological relationship of attenuated psychosis syndrome (APS) to schizotypal personality disorder and other psychiatric conditions was unclear. Further study will hopefully resolve these questions. The work group decided to recommend the inclusion of attenuated psychosis syndrome as a category in the appendix (Section 3) of DSM-5 as a condition for further study.
Keywords: Attenuated psychosis syndrome; High risk; Intervention; Prodromes; Schizophrenia.
Copyright © 2013 Elsevier B.V. All rights reserved.
Similar articles
-
[Attenuated psychosis syndrome: A new diagnostic category for further study in DSM-5].Psychiatriki. 2017 Apr-Jun;28(2):120-130. doi: 10.22365/jpsych.2017.282.120. Psychiatriki. 2017. PMID: 28686559 Greek, Modern.
-
[Changes to Schizophrenia Spectrum and other psychotic disorders in DSM-5].Z Kinder Jugendpsychiatr Psychother. 2014 May;42(3):193-202. doi: 10.1024/1422-4917/a000289. Z Kinder Jugendpsychiatr Psychother. 2014. PMID: 24846868 Review. German.
-
Attenuated psychosis syndrome: ready for DSM-5.1?Annu Rev Clin Psychol. 2014;10:155-92. doi: 10.1146/annurev-clinpsy-032813-153645. Epub 2014 Jan 17. Annu Rev Clin Psychol. 2014. PMID: 24471375 Review.
-
The psychoses: cluster 3 of the proposed meta-structure for DSM-V and ICD-11.Psychol Med. 2009 Dec;39(12):2025-42. doi: 10.1017/S0033291709990286. Epub 2009 Oct 1. Psychol Med. 2009. PMID: 19796428 Review.
-
Exploring the borders of the schizoaffective spectrum: a categorical and dimensional approach.J Affect Disord. 2008 May;108(1-2):71-86. doi: 10.1016/j.jad.2007.09.009. Epub 2007 Oct 29. J Affect Disord. 2008. PMID: 18029027
Cited by
-
Understanding Cortical Dysfunction in Schizophrenia With TMS/EEG.Front Neurosci. 2020 May 28;14:554. doi: 10.3389/fnins.2020.00554. eCollection 2020. Front Neurosci. 2020. PMID: 32547362 Free PMC article. Review.
-
Focus on psychosis.Dialogues Clin Neurosci. 2015 Mar;17(1):9-18. doi: 10.31887/DCNS.2015.17.1/wgaebel. Dialogues Clin Neurosci. 2015. PMID: 25987859 Free PMC article. Review.
-
Auditory Event-Related Potentials in Antipsychotic-Free Subjects With Ultra-High-Risk State and First-Episode Psychosis.Front Psychiatry. 2019 Apr 15;10:223. doi: 10.3389/fpsyt.2019.00223. eCollection 2019. Front Psychiatry. 2019. PMID: 31037058 Free PMC article.
-
Altering the course of schizophrenia: progress and perspectives.Nat Rev Drug Discov. 2016 Jul;15(7):485-515. doi: 10.1038/nrd.2016.28. Epub 2016 Mar 4. Nat Rev Drug Discov. 2016. PMID: 26939910 Review.
-
Refining antipsychotic treatment strategies in schizophrenia: discovery of genetic biomarkers for enhanced drug response prediction.Mol Psychiatry. 2025 Jun;30(6):2362-2371. doi: 10.1038/s41380-024-02841-w. Epub 2024 Nov 19. Mol Psychiatry. 2025. PMID: 39562719
References
-
- Amminger GP, Schafer MR, Papageorgiou K, et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2010;67:146–154. - PubMed
-
- Boonstra N, Klaasen R, Sytema S, et al. Duration of untreated psychosis and negative symptoms- A systematic review and meta-analysis of individual patient data. Schizophr Res. 2012;142:12–19. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous